| abstract |
The present invention provides a novel crystal form having a factor Xa inhibitory effect and excellent stability. 1,2-Pyrrolidinedicarboxamide, N1- (4-chlorophenyl) -N2- [2-fluoro-4- (2-oxo-1 (2H)-, identified by powder X-ray diffraction and solid-state NMR Crystal forms A, B, and C of pyridinyl) phenyl] -4-methoxy, (2R, 4R)-(9Cl). And pharmaceutical compositions comprising their crystalline forms. [Selection] Figure 1 |